I thought it was interesting that last few updates have steered...

I thought it was interesting that last few updates have steered away from talk of finding cell specific fpp's and instead talk of success with systemic injection. Maybe a small pivot took place ? I assume this may be one reason we are now targetting the eye, ie systemic injection to the eye and not the whole body with sink effect discussed previously. I guess the previous change to targetting blood bourne cancers with imyc was to try and penetrate whatever we contacted first as the lead fpps still appear to be quite generalized. Maybe the cell penetration was still too global and we changed to eye to reduce the target area again. Either way i guess a sensible move if it turns out to be something that can actually be pushed forward towards market or deals
It offers treatment possibilities for currently hard to treat indications, and still showcases the possibilities of the platform while maybe we search for more cell specific fpps. I am sure there are plenty working in the eye area who will be very interested.

I get the impression that it may be difficult to actually target a specific organ in the body with systemic injection and maybe a more local injection to target cells might be the outcome. Either way nice to see a bit of interest but no real volume yet.